Bristol-Myers Squibb
BMY
1,595 hedge funds and large institutions have $64B invested in Bristol-Myers Squibb in 2017 Q2 according to their latest regulatory filings, with 105 funds opening new positions, 575 increasing their positions, 658 reducing their positions, and 88 closing their positions.
20% more call options, than puts
Call options by funds: $1.81B | Put options by funds: $1.51B
19% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 88
1% more capital invested
Capital invested by funds: $63.5B → $64B (+$485M)
0% less funds holding
Funds holding: 1,598 → 1,595 (-3)
1.17% less ownership
Funds ownership: 70.75% → 69.58% (-1.2%)
2% less funds holding in top 10
Funds holding in top 10: 45 → 44 (-1)
13% less repeat investments, than reductions
Existing positions increased: 575 | Existing positions reduced: 658
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$382M |
| 2 |
Primecap Management
Pasadena,
California
|
+$247M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$215M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$191M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$181M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$548M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$357M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$342M |
| 4 |
Morgan Stanley
New York
|
-$281M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$128M |
BMY Hedge Fund Activity: Q2 2017 in Review
1,595 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2017, worth a combined $64B — up 0.76% from $63.5B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new BMY positions and 88 closed out — a net gain of 17 holders — while 575 added to existing stakes and 658 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $382M. The largest seller was T. Rowe Price Associates, cutting an estimated $548M.
- 1,595 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2017, down from 1,598 in Q1 2017.
- Funds reported $64B of Bristol-Myers Squibb stock for Q2 2017, up 0.76% quarter-over-quarter.
- 105 funds opened new Bristol-Myers Squibb positions in Q2 2017 and 88 closed out, a net change of +17 holders.
- The largest Bristol-Myers Squibb buyer in Q2 2017 was Renaissance Technologies, an estimated $382M added.
- The largest Bristol-Myers Squibb seller in Q2 2017 was T. Rowe Price Associates, an estimated $548M sold.
Based on aggregated 13F filings for Q2 2017.